Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report sent to investors on Friday morning,Benzinga reports. They currently have a $50.00 target price on the stock.

DYN has been the subject of several other research reports. Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price for the company. Piper Sandler reduced their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Friday. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Finally, Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.64.

Dyne Therapeutics Price Performance

DYN opened at $13.61 on Friday. The company’s 50 day moving average price is $16.98 and its two-hundred day moving average price is $27.50. Dyne Therapeutics has a fifty-two week low of $12.87 and a fifty-two week high of $47.45. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -3.82 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. As a group, equities research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares in the company, valued at $3,573,433.36. The trade was a 1.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,387 shares of company stock valued at $142,789 in the last quarter. 20.77% of the stock is owned by insiders.

Institutional Trading of Dyne Therapeutics

Hedge funds have recently modified their holdings of the company. State of New Jersey Common Pension Fund D purchased a new stake in Dyne Therapeutics during the 3rd quarter valued at $1,588,000. Jennison Associates LLC raised its holdings in Dyne Therapeutics by 1.5% during the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after buying an additional 19,730 shares during the period. abrdn plc purchased a new stake in Dyne Therapeutics during the 4th quarter valued at $608,000. RA Capital Management L.P. raised its holdings in Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after buying an additional 331,940 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Dyne Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock valued at $66,802,000 after buying an additional 84,760 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.